Last night, SyntheticMR announced the acquisition of Combinostics, a medtech and software company that offers advanced diagnostic solutions. Combinostics has sales LTM Q3/24 sales of SEK 10.5m (77% growth from 2023) and EBITDA of SEK -3.3m. SyntheticMR pays SEK 49.6m, corresponding to an EV/sales of 4.7x. It also announced a preferential rights issue with gross proceeds of SEK 65m. SEB is advisor to SyntheticMR for the rights issue.

Länk till analysen